Innovate Biopharmaceuticals Inc (NASDAQ:INNT) Expected to Announce Earnings of -$0.13 Per Share

Share on StockTwits

Analysts expect that Innovate Biopharmaceuticals Inc (NASDAQ:INNT) will post earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Innovate Biopharmaceuticals’ earnings. Innovate Biopharmaceuticals reported earnings of ($0.11) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 18.2%. The firm is scheduled to issue its next quarterly earnings report on Monday, March 16th.

On average, analysts expect that Innovate Biopharmaceuticals will report full-year earnings of ($0.58) per share for the current financial year. For the next fiscal year, analysts expect that the company will post earnings of ($0.68) per share. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Innovate Biopharmaceuticals.

INNT has been the topic of several research analyst reports. ValuEngine upgraded shares of Innovate Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Zacks Investment Research lowered shares of Innovate Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th.

Shares of Innovate Biopharmaceuticals stock traded down $0.03 during midday trading on Thursday, reaching $0.75. 1,177 shares of the company’s stock traded hands, compared to its average volume of 283,177. The stock has a 50 day moving average of $0.87 and a 200-day moving average of $1.04. The company has a market cap of $27.99 million, a PE ratio of -0.78 and a beta of -2.48. Innovate Biopharmaceuticals has a 12 month low of $0.71 and a 12 month high of $4.32.

A number of institutional investors and hedge funds have recently bought and sold shares of INNT. Paloma Partners Management Co purchased a new position in Innovate Biopharmaceuticals during the second quarter valued at $104,000. Vanguard Group Inc. boosted its holdings in shares of Innovate Biopharmaceuticals by 14.5% during the 2nd quarter. Vanguard Group Inc. now owns 955,144 shares of the company’s stock valued at $1,108,000 after buying an additional 121,104 shares in the last quarter. Finally, GSA Capital Partners LLP grew its position in shares of Innovate Biopharmaceuticals by 59.6% in the 2nd quarter. GSA Capital Partners LLP now owns 64,786 shares of the company’s stock worth $75,000 after buying an additional 24,186 shares during the period. Institutional investors and hedge funds own 7.44% of the company’s stock.

About Innovate Biopharmaceuticals

Innovate Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH).

Further Reading: What is Blockchain?

Get a free copy of the Zacks research report on Innovate Biopharmaceuticals (INNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innovate Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovate Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.